Target family: Formylpeptide receptors (type: gpcr)
Target: FPR2

Ligand: WKYMVm (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10.13 pKd
Reference (Journal): The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor.
Published in: J Immunol

Ligand: V3 peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Activation of the chemotactic peptide receptor FPRL1 in monocytes phosphorylates the chemokine receptor CCR5 and attenuates cell responses to selected chemokines.
Published in: Biochem Biophys Res Commun

Ligand: uPar fragment (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.08 pEC50
Reference (Journal): The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R.
Published in: Proc Natl Acad Sci USA

Ligand: t-Boc-FLFLF (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor.
Published in: Inflammation

Ligand: t-Boc-FLFLF (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Formyl peptide chemoattractants: a model of the receptor on rabbit neutrophils.
Published in: Biochemistry

Ligand: t-Boc-FLFLF (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR.
Published in: Mol Cell

Ligand: T21/DP107 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.3 pEC50
Reference (Journal): T21/DP107, A synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors.
Published in: J Immunol

Ligand: [3H]LXA4 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.3 pKd
Reference (Journal): A novel rat lipoxin A4 receptor that is conserved in structure and function.
Published in: Br J Pharmacol

Ligand: [3H]LXA4 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils.
Published in: J Biol Chem

Ligand: [3H]LXA4 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.82 pKd
Reference (Journal): Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors.
Published in: J Exp Med

Ligand: [3H]LXA4 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor.
Published in: J Exp Med

Ligand: [125I-Tyr]Ac2-26 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.89 pKd
Reference (Journal): Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor.
Published in: Nat Med

Ligand: [125I-Tyr]Ac2-26 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.09 pKd
Reference (Journal): A novel rat lipoxin A4 receptor that is conserved in structure and function.
Published in: Br J Pharmacol